Global perspectives on lupus nephritis: a review of clinical trials and therapeutic innovations Authors: Jiaruo Xu, Yongkang Zhang, Hui Huang, Yemin Cao Published: 2026 ABSTRACT Background and objectivesLupus nephritis (LN) remains a leading cause of morbidity and mortality in systemic lupus erythematosus (SLE). Although recent years have witnessed the approval of several targeted therapies, achieving long-term, drug-free remission remains challenging. This commentary evaluates the global landscape of interventional LN clinical trials from 2001 to 2026 to identify emerging trends and strategic gaps in drug development.MethodsWe analyzed 200 interventional pharmacological trials retrieved from three major global registries: ClinicalTrials.gov, Chinadrugtrials.org, and ISRCTN. Trials were systematically categorized by study phase, geographic distribution, and therapeutic mechanism, with data synthesized to reflect the transition from non-specific immunosuppression to precision-targeted approaches.Key findingsOur analysis indicates an accelerating trend in Phase II/III trials, with a notable geographic shift toward the Asia-Pacific region. We identify a diversification of therapeutic targets beyond B-cell depletion (e.g., obinutuzumab) to include complement inhibitors, intracellular signaling blockers (BTK and JAK inhibitors), and novel immune-reset strategies such as CAR-T therapy. Despite these innovations, complete renal response rates in pivotal trials often plateau at 40-50%, suggesting a persistent “ceiling effect”.Conclusion and implicationsTo break current therapeutic plateaus, future research must prioritize: (1) integrating pharmacogenomics (e.g., CYP3A5 and TPMT genotyping) for personalized drug selection; (2) developing steroid-fast-tapering or steroid-free induction protocols to minimize toxicity; and (3) validating real-time molecular biomarkers to replace lagging clinical indicators. This data-driven perspective provides a practical framework for refining trial designs and achieving precision medicine in LN. Introduction Lupus nephritis (LN) is the most common and severe renal complication associated with systemic lupus erythematosus (SLE), an autoimmune disorder characterized by widespread inflammation and tissue damage (Figure 1A). It affects more than 30%-60% of patients with SLE, and renal biopsy reveals evidence of renal involvement in nearly 100% of cases, underscoring the critical role of renal manifestations in the disease progression (2). Clinical manifestations of renal damage can vary widely among patients, ranging from mild proteinuria and hematuria to severe nephritis, which can lead to renal failure (3, 4). Currently, there is no standardized treatment protocol for LN. The primary goals are to control lupus activity, prevent the progression of renal damage, and minimize the side effects associated with drug therapy. The global landscape and therapeutic evolution of clinical trials in LN (2001– 2026). (A) global distribution of SLE incidence. The heatmap illustrates the global burden of SLE, and the red shading indicates regions with higher reported incidence/prevalence (76, 1). (B) temporal trends in interventional drug trials. The bar graph depicts the number of registered interventional clinical trials for LN from January 1, 2001, to 2026. Data were aggregated from ClinicalTrials.gov, Chinadrugtrials.org, and ISRCTN. The analysis includes 200 selected trials focusing on pharmacological interventions, excluding observational studies. (C) classification of therapeutic mechanisms. Therapeutic agents identified in the survey (Table 2) are categorized by their primary mechanism of action. (D) reversibility of drug action. The chart illustrates the binding characteristics of the identified agents. Reversible (89.71%) refers to non-covalent binding agents (e.g., most monoclonal antibodies and reversible small molecules), whereas Irreversible (1.47%) refers to covalent inhibitors (e.g., certain BTK inhibitors) that permanently disable the target protein until new synthesis occurs. LN, lupus nephritis; SLE, systemic lupus erythematosus. The 2025 update to the EULAR recommendations for managing LN represents a significant refinement of the therapeutic framework (5). It consolidates a more proactive and goal-oriented strategy, with complete renal remission, defined by specific thresholds of proteinuria and stable renal function, serving as the paramount treatment objective. The standard protocol consists of an induction of remission phase followed by maintenance therapy, with rigorous supportive care integrated throughout (6). For induction therapy, mycophenolate mofetil (MMF) or low-dose cyclophosphamide (CTX), each combined with glucocorticoids, remains foundational. Notably, the update elevates the role of calcineurin inhibitor-based regimens, particularly the combination of voclosporin with MMF, for high-risk or proliferative disease. Maintenance therapy continues to prioritize MMF or azathioprine, with an emphasis on adequate treatment duration. The guidance also clarifies the additive benefit of belimumab to standard therapy and suggests a broader potential role for rituximab in refractory cases. Throughout, stringent supportive care, including hydroxychloroquine use, blood pressure control, and regular monitoring via renal activity indices, is underscored as integral to management. However, despite these advances, a significant proportion of patients fail to achieve complete renal response. This review analyzes global clinical trial data since 2000 to evaluate the evolution of treatment strategies, assess the efficacy of emerging targeted therapies, and identify critical unmet needs in LN management. Methods To provide a data-driven perspective on the evolution of LN therapy, we conducted a systematic search of global clinical trial registries. Search strategy and data sources We queried four major international registries: ClinicalTrials.gov, Chinadrugtrials.org, and the UK’s Clinical Study Registry (ISRCTN), among others. The search was performed for interventional trials registered from January 1, 2001, to 2026. The primary search term used was “lupus nephritis”. Inclusion and exclusion criteria Trails were included if they met the following criteria: Study type: interventional drug trials; Study type: interventional drug trials; Phase: trials ranging from Phase I to IV. Phase: trials ranging from Phase I to IV. We excluded: Observational studies and diagnostic/biomarker validation trials; Observational studies and diagnostic/biomarker validation trials; Non-pharmacological interventions (e.g., dietary or lifestyle-based studies); Non-pharmacological interventions (e.g., dietary or lifestyle-based studies); Trials with a status of “Withdrawn” or “Unknown”. Trials with a status of “Withdrawn” or “Unknown”. Data extraction and categorization A total of 200 trials were retrieved and indexed by their unique registration numbers (e.g., NCT, CTR, or ISRCTN). In this analysis, each registration number was treated as an independent entry to reflect the total volume of registered clinical activity, including multi-center extensions or platform-specific registrations. Extracted data included the trials phase, start year, intervention/treatment name, geographic region of the study sites, and LN class (see Table 1). To ensure scientific rigor, the therapeutic mechanism of action was cross-referenced using Pharmacodia (mdata.pharmacodia.com) and BCPM (pharma.bcpmdata.com) databases, with detailed target classifications summarized in Table 2. Table 1The clinical trial research worldwide from 2000 to 2026.Registration NumberPhasesStart TimeIntervention/TreatmentRegionTypes of LNNCT00204022 (Completed)Phase III2001MMF, AzathioprineBelgium NCT00046774 (Completed)Phase I2002MRA (anti-IL-6R monoclonal antibody)United States NCT00001789 (Completed)Phase II2002BG9588 (anti-CD40L Antibody)United StatesIII, IVNCT00976300 (Completed)Phase II2002Cyclosporine A, Intravenous Cyclophosphamide (CTX)CzechiaIII, IVNCT00050713 (Completed)Phase II2002SirolimusUnited States NCT00429377 (Completed)Phase III2003Tacrolimus (FK506)Japan NCT01207297 (Completed)Phase I2003TAC, CTXChinaIII+V, IV +/- V, VNCT00094380 (Completed)Phase I, II2004CTLA4-IgG4m (RG2077)+CTXUnited StatesIII, IV, VNCT00089804 (Terminated)Phase III2004Abetimus sodium (LJP 394)United States, Argentina, Australia, Belarus, Brazil, Bulgaria, Czechia, Georgia, Germany, Hong Kong (China), Hungary, India, Indonesia, Italy, Lebanon, Malaysia, Mexico, Philippines, Poland, Portugal, Puerto Rico, Romania, Serbia, Slovakia, South Korea, Spain, Sri Lanka, Taiwan (China), Thailand, Ukraine NCT00125307 (Completed)Phase IV2004TACHong Kong (China)VNCT00268567 (Completed)Phase II, III2005Leflunomide+PrednisoneChina NCT00377637 (Completed)Phase III2005MMF+CTX, MMF+AzathioprineUnited States, Argentina, Australia, Belarus, Brazil, Canada, China, Czechia, France, Germany, Greece, Hungary, Italy, Mexico, Portugal, Spain, United Kingdom NCT00404794 (Completed)Phase III2005Prednisolone and MMF, or TACHong Kong (China)III, IVNCT00368264 (Terminated)Phase II, III2006Azathioprine + Infliximab (Anti-TNF-α Chimeric Monoclonal Antibody)Austria, Germany, NetherlandsVNCT00282347 (Completed)Phase III2006Rituximab+MMF III, IVNCT00371319 (Completed)Phase IV2006TAC, MMFHong Kong (China)III, IV, VNCT02081183 (Terminated)Phase III2006CellCept (MMF)VenezuelaIII, IV, VNCT01845740 (Completed)Phase I2007MilatuzumabUnited States NCT00430677 (Terminated)Phase II, III2007Abatacept+Corticosteroids+MMFUnited States, Argentina, Australia, Belgium, Brazil, Canada, China, France, India, Mexico, Poland, Russia, South Africa, South Korea, Turkey, United KingdomIII, IVNCT00573157 (Terminated)Phase II, III2007Atacicept+MMF+CorticosteroidsUnited States, Czechia, Malaysia, Singapore, Taiwan(China)III, IVNCT00423098 (Completed)Phase II2007Mycophenolate sodium combinate with Prednisone or MethylprednisoloneColombia, France, Germany, Greece, Hungary, Italy, Spain, Taiwan (China), United KingdomIII, IVNCT00425438 (Terminated)Phase III2007CellCept (MMF)China NCT00479622 (Terminated)Phase I2007TRU-015United StatesVNCT00709722 (Completed)Phase I, II2008Deoxyspergualin (NKT-01)Czechia, Germany NCT00774852 (Completed)Phase II2008Abatacept+CTXUnited States, Mexico NCT00626197 (Terminated)Phase III2008Ocrelizumab III, IVNCT00615173 (Completed)Phase III2008Tacrolimus (FK506)ChinaIII, IV, VNCT00447265 (Terminated)Phase II2008EtanerceptUnited States NCT00705367 (Completed)Phase I2008AbataceptChina NCT01015456 (Terminated)Phase III2009enteric-coated mycophenolate sodium (Myfortic)ThailandIII, IVNCT01042457 (Completed)Phase III2009MMFThailandIII or IV (A or A/C) not include III(C) IV(C) and VI (>90% chronic irreversible scarring)NCT00818948 (Completed)Phase I2009AMG 811United States, France, Hong Kong (China), Malaysia, MexicoIII, IVNCT01203709 (Completed)Phase IV2010low-dose combination of MMF and TACHong Kong (China) NCT01085097 (Completed)Phase II2010LaquinimodUnited States, Canada, France, Russia, United KingdomIII+/- V, IV +/- V, VNCT01369628 (Terminated)Phase I2011Atacicept+MMFUnited StatesIII+/- V, IV +/- V, VNCT01407406 (Completed)Phase I2011BIIB023Australia, Hong Kong (China) NCT01273389 (Completed)Phase II2011CNTO 136United States, Belgium, Mexico, Netherlands, Poland, ThailandIII, IVNCT01342016 (Terminated)Phase III2011TAC Capsule+Leflunomide tabletChinaIII, IVNCT01328834 (Completed)Phase III2011TAC Sustained-release Capsules(ADVAGRAF)ChinaIII+/- V, IV +/- V, VNCT01316133 (Terminated)Phase IV2011TACSouth KoreaIII, IVNCT01284725 (Completed)Phase III2011MMF, azathioprineFranceIII+/-C+/- V, IV +/-C+/- VNCT01541670 (Terminated)Phase I2011Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) AntibodyUnited States, Australia, Canada, Mexico, New Zealand ISRCTN84672048 (Completed)Phase II2011recombinant human soluble Fc-gamma receptor IIb (SM101)United Kingdom, Australia, Belgium, Czech Republic, France, Germany, Italy, Poland, Spain NCT01499355 (terminated)Phase II2012BIIB023United States, Argentina, Australia, Belgium, Brazil, Colombia, France, Germany, Hong Kong (China), Hungary, Italy, Malaysia, Mexico, Peru, Philippines, Poland, Portugal, Russia, South Korea, Spain, ThailandIII+/- V, IV +/- VNCT01639339 (Completed)Phase III2012BelimumabUnited States, Argentina, Belgium, Brazil, Canada, China, Colombia, Czechia, France, Germany, Hungary, Mexico, Netherlands, Philippines, Russia, South Korea, Spain,Thailand,United Kingdom NCT01714817 (Terminated)Phase III2013Abatacept (BMS-188667)United States, Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Czechia, India, Israel, Italy, Japan, Mexico, Peru, Puerto Rico, Romania, Russia, South Korea, Spain, TurkeyIII, IVNCT01765842 (Terminated)Phase III2013RituximabSpain NCT01930890 (Terminated)Phase II2013BIIB023United States, Argentina, Australia, Belgium, Brazil, Colombia, France, Hong Kong (China), Hungary, Italy, Malaysia, Mexico, Peru, Philippines, Poland, Russia, South Korea, Spain, Thailand NCT01861561 (Terminated)Phase IV2013CTXThailand NCT02260934 (Completed)Phase II2014Rituximab+CTX/-BelimumabUnited StatesIII+/- V, IV +/- V, VNCT03200002 (Completed)Phase II2014CTX, MMF III, IV, VNCT02141672 (Completed)Phase II2014VoclosporinUnited States, Bangladesh, Belarus, Bulgaria, China, Ecuador, Georgia, Guatemala, Mexico, Philippines, Poland, Russia, Serbia, Singapore, South Korea, Spain, Sri Lanka, Thailand, UkraineIII, IVCTR20140883 (Completed)Phase III2014TAC, CTXChinaIII+/- V, IV +/- V, VCTR20140614 (Completed)Phase III2014HE-69ChinaIII+/- V, IV +/- V, VNCT02256150 (Completed)Phase III2014Mizoribine (MZR)ChinaIII+/- V, IV +/- V, VNCT02176486 (Terminated)Phase I2014IxazomibUnited States, France, Germany, Italy, Russia, Spain, United KingdomIII, IV, V [excluding Class III (C), IV-S (C),IVd and IV-G (C)]NCT04318600 (Completed)Phase I2014human amniotic mesenchymal stem cell III, IV,VNCT02547922 (Completed)Phase II2015AnifrolumabUnited States, Argentina, Australia, Belgium, France, Germany, Hungary, Italy, Mexico, Peru, Poland, Russia, Serbia, South Korea, Spain, Taiwan (China), United KingdomIII+/- V, IV +/- VNCT02550652 (Completed)Phase II2015Obinutuzumab+MMF/Mycophenolic Acid (MPA)United States, Argentina, Brazil, Colombia, Costa Rica, France, Israel, Italy, Mexico, Panama, Peru, SpainIII+/- V, IV +/- VNCT01773616 (Terminated)Phase III2015Rituximab+MMF Without Oral SteroidsUnited KingdomIII, IV-S, IV-G, VCTR20150079 (Completed)Phase III2015BelimumabChina, Russia, Canada, Hungary, Colombia, Mexico, Brazil, Germany, Chile, Belgium, France, Thailand, United States, United Kingdom, Philippines, Spain, Argentina, South KoreaIII+/- V, IV +/- V [excluding III(C), IV-S(C), and IV-G(C)], VCTR20140843Phase III2015BMS-188667China, Argentina, Australia, Brazil, Canada, Chile, Colombia, India, Israel, Italy, Japan, South Korea, Mexico, Puerto Rico, Romania, Russia, Turkey, United StatesIII, IV [excluding III (C), IV-S (C), and IV-G (C)]NCT02457221 (Completed)Phase III2015TAC Capsules+CTX InjectionChinaIII+/- V, IV +/- V, VNCT02630628 (Completed)Phase III2015TACHong Kong (China)III+/- V, IV +/- VNCT02949349 (Completed)Phase II2015MMF/Azathioprine formulation NCT02645565 (Completed)Phase IV2015CTX, Azathioprine, MethylprednisoloneIndiaIII, IVNCT02949973 (Completed)Phase II2015VoclosporinMalaysiaIII+/- V, IV-S or IV-G, (A) or (A/C), IV +/- V, VNCT02770170 (Completed)Phase II2016BI 655064United States, Australia, Canada, Czechia, France, Germany, Greece, Hong Kong (China), Italy, Japan, Malaysia, Mexico, Philippines, Poland, Portugal, Serbia, South Korea, Spain, Thailand, United KingdomIII+/- V, IV +/- VNCT02514967 (Terminated)Phase III2016BlisibimodGeorgia NCT02682407 (Terminated)Phase II2016Narsoplimab (OMS721)United States, Hong Kong (China) ISRCTN47873003 (Completed)Phase II2016Belimumab After B cell depletion therapyUnited Kingdom NCT03174587 (Completed)Phase I2017CS20AT04 Inj (allogenic bone marrow-derived mesenchymal stem cells)South KoreaIII, IV, VNCT03021499 (Completed)Phase III2017VoclosporinUnited States, Argentina, Belarus, Brazil, Bulgaria, Canada, Chile, Colombia, Costa Rica, Croatia, Dominican Republic, Guatemala, Japan, Malaysia, Mexico, Netherlands, North Macedonia, Peru, Philippines, Poland, Puerto Rico, Russia, Serbia, South Africa, South Korea, Spain, Taiwan (China), Thailand, Turkey, Ukraine, VietnamIII+/- V, IV +/- V, VNCT03393013 (Completed)Phase I, II2018KZR-616United States, Australia, Colombia, Mexico, Peru, Poland, Russia, UkraineIII+/- V, IV +/- V, VNCT03747159Phase III2018combination B-cell targeting by starting treatment with Belimumab (anti-BAFF), followed by Rituximab (anti-CD20)Netherlands NCT03597464 (Completed)Phase III2018MMF+VoclosporinUnited States NCT03610516 (Completed)Phase II2018CFZ533 (anti-CD40 monoclonal antibody)Argentina, China, Germany, Hungary, Russia, South Korea, Tunisia, TurkeyIII+/- V, IV +/- VNCT04146220 (Completed)Phase IV2018PrednisoloneBangladeshIII, IVNCT03385564 (Completed)Phase II2018BI 655064United States, Australia, Canada, Czechia, Germany, Greece, Hong Kong (China), Japan, Malaysia, Mexico, Philippines, Poland, Portugal, South Korea, Thailand, United KingdomIII, IVNCT03453619 (Completed)Phase II2018APL-2United StatesIII, IV,VNCT04128579 (Completed)Phase I2019Itolizumab [Bmab 600]United States, India, PolandIII+/- V, IV +/- VCTR20191068 (Completed)Phase II2019CFZ533China, South Korea, Germany, Russia, Argentina, Germany, Hungary, Russia, Tunisia, TurkeyIII, IVNCT03920059 (Terminated)Phase IV2019MMFThailandIII or IV [exclude III(c), IV-S(c) and IV-G(c)]+/- VNCT03943147 (Terminated)Phase II2019BMS-986165United States, Australia, Belgium, Canada, China, Czechia, Germany, Israel, Italy, Mexico, Netherlands, Russia, South Korea, Spain, United KingdomIII, IV-S, or IV-G; or VCTR20202662 (Completed)Phase II2020Zanubrutinib CapsulesChinaIII+/- V, IV +/- VCTR20200316 (Terminated)Phase II2020BMS-986165China, Argentina, Australia, Belgium, Brazil, Czech, Germany, Israel, Italy, Mexico, Holland, Russia, United Kingdom,III+/- V, IV +/- V, VNCT04181762 (Terminated)Phase III2020SecukinumabUnited States, Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Croatia, Czech, Denmark, France, Germany, Greece, Guatemala, India, Italy, Japan, Mexico, Norway, Peru, Philippines, Portugal, Romania, Russia, Slovakia, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, VietnamIII+/- V, IV +/- V, VCTR20201175 (Terminated)Phase III2020Secukinumab Injection III+/- V, IV +/- V, VNCT04643470 (Completed)Phase II2020ZanubrutinibChina[III(A), III (A+C), IV (A), and IV (A+C)]+/- VNCT04376827 (Terminated)Phase II2020GuselkumabUnited States, Argentina, Mexico, Poland, Russia, Spain, Taiwan (China), Thailand, UkraineIII+/- V, IV +/- VNCT04221477Phase III2020ObinutuzumabUnited States, Argentina, Brazil, Colombia, France, Germany, Israel, Italy, Mexico, Peru, Poland, Russia, South Africa, Spain, United Kingdom, South Korea, Spain, United StatesIII+/- V, IV +/- VISRCTN12809537Phase I2021CrovalimabArgentina, Colombia, Germany, Italy, Spain, United StatesIII+/- V, IV +/- VCTR20211541Phase I, II2021MIL62China NCT04868838Phase II2021DaratumumabUnited StatesIII+/- V, IV +/- VCTR20211337Phase II2021Vunakizumab (SHR-1314)ChinaIII+/- V, IV +/- VNCT04702256Phase III2021Oral Corticosteroids+MMF, Obinutuzumab+MMFFranceIII+/- V, IV +/- VNCT07044115Phase I, II2021Recombinant Humanized Monoclonal Antibody MIL62 InjectionChina NCT04424602 (Completed)Phase IV2021CTX, MycophenolateEgyptI, V, VINCT04564339 (Terminated)Phase II2021RavulizumabUnited States, Australia, Canada, France, Germany, Italy, Netherlands, Poland, South Korea, Spain, Taiwan (China), United KingdomIII, IVISRCTN80103507Phase II2021ORBCEL-C™United KingdomIII, IV, VCTR20222118 (Completed)Phase I2022HRS-5965 tabletsChina CTR20220218 (Completed)Phase I2022MMF CapsulesChina NCT05201469Phase II2022VIB4920+MMF+ PrednisoneUnited StatesIII+/- V, IV +/- V, VNCT03673748Phase II2022Mesenchymal stem cellsSpainIII+/- V, IV +/- VNCT05268289Phase II2022Iptacopan (LNP023)United States, Argentina, Brazil, China, Colombia, France, Germany, Hungary, India, Israel, Malaysia, Mexico, Philippines, Portugal, Puerto Rico, Singapore, Spain, Turkey, United KingdomIII+/- V, IV +/- VCTR20223334Phase II2022Telitacicept for InjectionChinaIII+/- V, IV +/- V, VNCT05126277Phase III2022IanalumabUnited States, Argentina, Brazil, Canada, Chile, China, Czechia, Estonia, France, Germany, Guatemala, Hungary, India, Italy, Lithuania, Malaysia, Mexico, Romania, Singapore, South Korea, Spain, Thailand, United Kingdom, VietnamIII+/- V, IV +/- V, VNCT00035308 (Completed)Phase III2022Abetimus sodium (LJP 394)United States, Austria, Canada, France, Germany, Italy, Mexico, Spain, Sweden, United Kingdom CTR20223330 (Terminated)Phase III2022Secukinumab InjectionChina, Czechia, Japan, Thailand, Spain, Slovakia, South Korea, Portugal, Guatemala, Colombia, Philippines, Brazil, Vietnam CTR20221549Phase III2022Anifrolumab Solution for InjectionChina, Argentina, France, Germany, Hungary, India, Italy, Japan, Norway, Mexico, Poland, Russia, Thailand, Turkey, United States, Vietnam, Argentina, Belgium, Brazil, Bulgaria, Colombia, Malaysia, PeruIII+/- V, IV +/- VCTR20220030Phase III2022Gazyva InjectionChinaIII, IV, VNCT05704088 (Completed)Phase IV2022DapagliflozinEgypt NCT05232864 (Terminated)Phase III2022SecukinumabAustralia, Brazil, Colombia, Czechia, Guatemala, Japan, Philippines, Portugal, Slovakia, South Korea, Spain, Thailand, Vietnam NCT05207358Phase IV2022Rituximab, MMF, CTX, CorticosteroidsRomaniaIII, IV +/- VNCT05138133Phase III2022AnifrolumabUnited States, Argentina, Belgium, Brazil, Bulgaria, China, Colombia, France, Germany, Hungary, India, Italy, Japan, Malaysia, Mexico, Netherlands, Peru, Poland, Puerto Rico, Russia, Thailand, Turkey, VietnamIII+/- V, IV +/- VNCT05780515 (Completed)Phase I2022ANX009Philippines, Taiwan (China)III+/- V, IV +/- VNCT05039619Phase II2022ObinutuzumabUnited States, Brazil, Canada, France, Italy, Mexico, Peru, Poland, Russia, South Africa, Spain, United KingdomIII, IV [exclude isolated Class V]NCT06342960Phase I, II2022KYV-101 (anti-CD19 CAR-T cell therapy)GermanyIII, IVNCT05748925 (Completed)Phase IV2022sodium glucose linked transoprter inhibitors(SGT2i)Egypt NCT05097989 (Terminated)Phase II2022ALXN2050United States, Argentina, Australia, Brazil, China, Germany, Israel, Italy, Mexico, Serbia, South Korea, Spain, Thailand, Turkey, United KingdomIII, IVNCT05314231 (Completed)Phase I2022ALXN1720South Korea CTR20234139 (Completed)Phase I2023HSK39297 tabletsChina NCT06058078Phase II2023RY_SW01 Cell Injection (allogonic umbilical cord-derived mesenchymal stem cells, UCMSCs)ChinaIII+/- V, IV +/- V, VNCT06155604Phase II2023DapagliflozinHong Kong (China)III, IV, VCTR20232195 (Terminated)Phase II2023ALXN2050China, United States, Mexico, Germany, Israel, Italy, Spain, Thailand, United Kingdom, Australia, South Korea, Argentina, Brazil, Turkey, Peru, SerbiaIII+/- V, IV +/- V, VCTR20230354Phase II2023GR1501 injectionChinaIII+/- V, IV +/- VNCT05916781Phase IV2023MMF+TACChina NCT05714670 (Completed)Phase II2023Curcumin Oral CapsuleEgypt NCT05680480Phase II2023TelitaciceptChinaIII, IV, VNCT06406205Phase III2023Voclosporin(QL1074)ChinaIII, IV, VNCT06064929Phase I2023FelzartamabUnited States, Argentina, Australia, CanadaIII, IV, VNCT05810948 (Completed)Phase II2023Efgartigimod IVChinaIV-S(C), IV-G(C), VNCT05781750 (Terminated)Phase II2023Zetomipzomib(KZR-616)United States, Argentina, Brazil, China, Colombia, Greece, Guatemala, India, Malaysia, Philippines, South Africa, South KoreaIII+/- V, IV +/- VNCT05288855 (Terminated)Phase III2023VoclosporinUnited States, Colombia, Japan, Mexico, Thailand NCT05798117Phase I, II2023CYTB323G12101Australia, France, Germany, Spain, Switzerland NCT05938725Phase I, II2023KYV-101 (anti-CD19 CAR-T cell therapy)United StatesIII, IVNCT05508009Phase I, II2023Hematopoietic Stem Cell Transplantation (HSCT)United States NCT05732402Phase I, II2023PovetaciceptUnited States, Australia, Puerto Rico, South KoreaIII+/- V, IV +/- VISRCTN85816718Phase III2023ObinutuzumabChinaIII, IVCTR20243214 (Completed)Phase I2024[14C] HSK39297China NCT06350110Phase I, II2024BH002 injection (Fourth-gen CAR T Cells )China NCT05538208Phase II2024MMF (PLUMM)United StatesIII+/- V, IV +/- VNCT06681337(Not yet recruiting)Early Phase I2024BCMA CART+CD19 CART III, IV, VNCT07225387Phase IV2024Belimumab+VoclosporinUnited StatesIII+/- V, IV +/- VNCT05962788 (Terminated)Phase III2024VoclosporinUnited States, Colombia, Japan, Mexico, Thailand NCT06581198Phase II2024Rapcabtagene autoleucel (administered once following lymphodepletion)United States, Australia, Austria, Brazil, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Netherlands, Norway, Romania, Saudi Arabia, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan (China), United Kingdom NCT06121297Phase I, II2024CABA-201(an investigational cell therapy)United States, Canada, SpainIII+/- V, IV +/- VNCT06585514Phase I, II2024CD19 CAR-T cellsChinaIII, IVa [excluding III (C), IV-S (C) and IV-G (C)],VNCT06497387Early Phase I2024PRG-1801(CAR-T Cells)China NCT06497361Early Phase I2024PRG-2311(CAR-T Cells)ChinaIII+/- V, IV +/- V, VNCT06265220Phase I2024AB-101(an Allogeneic Cord Blood- Derived NK-Cell Therapy)United StatesIII+/- V, IV +/- VNCT06557265Phase I, II2024NKX019(a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy)United States, Puerto RicoIII+/- V, IV +/- VNCT06434363Phase I, II2024TafasitamabUnited States NCT06518668Phase I2024NKX019 (a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy)United StatesIII+/- V, IV +/- VNCT06152172Phase I2024KYV 101 (CAR-T therapy)United States NCT06285279Phase I2024FKC288 (CAR-T Cell)ChinaIII, IV,VNCT06294236Phase I2024SC291 (CAR-T Cell)United StatesIII, IVNCT06375993Phase I2024ADI-001 (Anti-CD20 CAR-engineered Allogeneic Gamma-Delta (γδ) T Cells)United StatesIII+/- V, IV +/- VNCT07053800(Not yet recruiting)Phase II2025Obecabtagene autoleucel III, IV, VNCT06785519Early Phase I2025CD19/BCMA Targeted CAR T-cells injectionChinaIII, IV, VNCT06711887Phase III2025IanalumabBrazil, China, Colombia, Hungary, Mexico, Romania, Singapore, South Korea, Taiwan (China), Thailand NCT06904729Phase III2025CAR-T cellsChinaIII, IVNCT06717815Phase I, II2025IPG11406ChinaIII, IV, VNCT06975787Phase I2025Vonsetamig, OdronextamabUnited States, Germany, South Korea, Spain, Taiwan (China) NCT07363460Phase II2025HSK39297ChinaIII+/- V, IV +/- VNCT07229742Phase II2025SHR-2173 InjectionChinaIII+/- V, IV +/- VNCT07015983Phase II2025CC-97540,Fludarabine,CTXUnited States, Argentina, Austria, Belgium, Brazil, Canada, Denmark, France, Germany, Israel, Italy, Japan, Netherlands, Poland, Portugal, Spain, United Kingdom NCT07340463Phase II2025Belimumab, TelitaciceptChinaIII+/- V, IV +/- VNCT06676631Phase I2025NK010 or NK042 Cell Injection+RituximabChinaIII+/- V, IV +/- VNCT06544330Phase I2025SYNCAR-001 + STK-009(receptor-ligand cell therapy)United StatesIII[C], IV-S[C], or IV-G[C]NCT07038382Phase II2025HLX79 (Human Sialidase Fusion Protein) in Combination With Rituximab Injection (HLX01, Anti-CD20 Antibody)China NCT06943937Phase I2025YTS109 cell injection(STAR-T cell therapy)China NCT07000292 (Not yet recruiting)Phase I, II2025MSC303China NCT07035834 (Not yet recruiting)Phase IV2025Gliflozin NCT07038447Phase I2025KITE-363 (CAR T-cell Therapy)United States, Australia, CanadaIII+/- V, IV +/- VNCT06839976Phase I, II2025CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19)United StatesIII+/- V, IV +/- VNCT06897930Phase I, II2025AZD0120 (CAR-T Therapy)United States, AustraliaIII, IV, VNCT06255028Phase I2025CNTY-101 (CAR iNK Cell)United StatesIII+/- V, IV +/- VNCT06708845(Not yet recruiting)Phase I2025zamtocabtagene autoleucel (CAR-T therapy) NCT06925542Phase I2025CTX112 (Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells)United States, Germany NCT06653556Early Phase I2025LCAR-AIO T cellsChina NCT07085104Phase I2025ALLO-329 (CAR T Cell)United States, Canada NCT06947460PhaseI, II2025CD19-BCMA CAR-T cells infusionChinaIII+/- V, IV +/- V[excluding type III (C), IV-S (C), and IV-G (C)]NCT07104721Phase I2025YTS109 cell injection (STAR-T cell therapy)China NCT07123519Phase I2025YTS109 cell injection (STAR-T cell therapy)China NCT06792799Early Phase I2025KN5601(CAR NK cells)China NCT07305116Phase I2025UCAR T-cellChina NCT07201129Phase III2026CenerimodUnited StatesIII+/- V, IV +/- V, VNCT07323524 (Not yet recruiting)Phase IV2026Dapagliflozin (10Mg Tab)United StatesIII+/- V, IV +/- V, VNCT07364396 (Not yet recruiting)Phase I, II2026CRC01 III+/- V, IV +/- VNCT06935474 (Not yet recruiting)Phase I, II2026C-CAR168United StatesIII+/- V, IV +/- VNCT07412210 (Not yet recruiting)Early Phase I2026AXA-NK02 III+/- V, IV +/- VNCT07107659Early Phase I2026ONT01United StatesIII+/- V, IV +/- V, VNCT07328581 (Not yet recruiting)Phase I, II2026ICG318 III+/- V, IV +/- V, VNCT07491900Phase I2026HB2198(a Tetravalent Bispecific Anti-CD19/CD20 Antibody With Dual Fc Domains)AustraliaIII+/- V, IV +/- V, VNCT06984341Phase I2026P-CD19CD20-ALLO1 CellsUnited StatesIII+/- V, IV +/- VNCT06947473PhaseI, II2026umbilical cord blood CD19-BCMA CAR-T cells infusionChinaIII+/- V, IV +/- V[excluding type III (C), IV-S (C), and IV-G (C)]NCT07236762Phase I2026YTS109 cell injection (STAR-T cell therapy)ChinaIII+/- V, IV +/- VNCT07507201Early Phase I2026UCAR T-cellChina CTR20261341Phase I2026CevostamabChina, Argentina, Australia, Brazil, France, Germany, Italy, SpainIII+/- V, IV +/- V The clinical trial research worldwide from 2000 to 2026. Table 2Overview of therapeutic agents for LN.CategoryAgent nameMechanism of actionApproval statusNotesAgents with Regulatory Approval for LNBelimumabBLyS (BAFF) inhibitorFDA (2020/2023), EMA (2021), NMPA (2022)The world's first biologic agent approved for the treatment of active LN for both adults (2020) and children (2023).VoclosporinNovel CNIFDA (2021, in combination with MMF), EMA (2022)The first oral medication approved for the treatment of active lupus nephritis.TacrolimusCNIPMDA (Japan) Approved, NMPA (China) ApprovedIn the United States (FDA), it has been approved for use in organ transplant rejection, and LN is an off-label use (i.e., beyond its approved indication). However, in Asia, it has been approved for use in LN.Agent NameMechanism of ActionStatus & Clinical PositioningConventional Standard of Care/ Off-Label UseMMFIMPDH InhibitorGuideline Preferred First-Line Agent. FDA approved for organ transplantation. Used off-label for LN induction & maintenance.MPSIMPDH InhibitorAlternative to MMF (often better tolerated). Off-label use for LN.CYCAlkylating AgentGuideline Preferred for Severe/Life-threatening LN. (Includes NIH high-dose or Euro-Lupus low-dose protocols). Approved for oncology/nephrotic syndrome, standard for severe LN.HCQTLR 7/9 AntagonistBase Therapy for ALL LN patients. FDA approved for SLE/Discoid Lupus. Recommended by all guidelines to prevent flares and reduce damage.Glucocorticoids (Prednisone / Methylprednisolone)Anti-inflammatory / Genomic effectsCornerstone of Induction. Used in combination with MMF/CYC. (Pulse IV therapy followed by oral tapering).AZAPurine Synthesis InhibitorMainly for Maintenance / Pregnancy. FDA approved for renal transplantation/RA. Second-line maintenance option or for pregnant patients.RTXAnti-CD20 Monoclonal AntibodyRescue Therapy for Refractory LN. FDA approved for NHL/RA/GPA. Used off-label for patients unresponsive to MMF/CYC (based on guidelines despite LUNAR trial failure).CsACNISecond-line / Alternative. FDA approved for transplantation. Used in LN (especially for proteinuria reduction or pregnancy) but largely replaced by Tacrolimus/Voclosporin.LeflunomidePyrimidine Synthesis InhibitorAlternative Maintenance Agent. FDA approved for RA. Used off-label for LN maintenance (especially in Asian populations/Chinese guidelines).MizoribineIMPDH InhibitorRegional Use (Japan/China). Approved in Japan for LN. Rarely used in Western countries.DapagliflozinSGLT2 inhibitor (Blocks glucose reabsorption; hemodynamic modulation)Guideline-Recommended Adjunctive Therapy. Approved for CKD/Heart Failure. KDIGO 2024 recommends use in LN to reduce proteinuria and delay CKD progression (Non-immunosuppressive).SirolimusmTOR inhibitor (Inhibits T-cell activation and proliferation)Off-Label / Second-Line Option. FDA approved for renal transplantation. Used in LN for specific refractory cases or to minimize CNI/steroid toxicity (mTOR pathway blockade).Agent NameTarget/Mechanism of ActionClinical Trial Status for LNOther Approved IndicationsInvestigational Agents in Advanced Development (Phase III)ObinutuzumabCD20 (Type II mAb)Phase III (REGENCY Trial). Recently met primary endpoints (2024 data)FDA Approved for CLL / Follicular Lymphoma.AnifrolumabIFNARPhase III (IRIS/TULIP-LN) ongoing.FDA Approved for SLE (non-renal) in 2021.TelitaciceptDual BLyS/APRIL inhibitorPhase III (Global & China).NMPA (China) Approved for SLE (2021). FDA Fast Track for SLE.Dapirolizumab pegolCD40L antagonistPhase III (PHOENYCS GO) ongoing.None (Investigational).Ianalumab (VAY736)BAFF-R (Depletion & Blockade)Phase III (SIRIUS-LN) ongoing.Investigational (Sjögren's, etc.).SecukinumabIL-17A inhibitorPhase III (SELUNE) ongoing.FDA Approved for Psoriasis / AS.ZanubrutinibBTK inhibitorPhase II/III (Ongoing).FDA Approved for Mantle Cell Lymphoma / CLL.OrelabrutinibBTK inhibitorPhase II/III (Ongoing).NMPA Approved for Lymphoma.Iptacopan (LNP023)Factor B (Alternative Pathway Complement Inhibitor)Phase III (APPEAL Study) ongoing.FDA Approved for IgA Nephropathy & PNH (Fabhalta).TherapiesAgent NameTarget/Mechanism of ActionClinical StatusSignificance / NotesEmerging Candidates in Early Phase (Phase I/II) & Novel ModalitiesCellular TherapiesCD19 CAR-T (e.g., Tisagenlecleucel, KYV-101/CABA-201)CD19 (Chimeric Antigen Receptor T-Cell)Phase I/II (Multiple trials ongoing).Aiming for "Drug-free Remission" by deep B-cell depletion. High attention due to recent NEJM/Nat Med case series.BCMA-CD19 CAR-TDual CD19+BCMAPhase I (Investigational).Targets both B cells and Plasma cells to prevent autoantibody recurrence.MSCsImmunomodulation / Tissue RepairPhase I/II (Multiple sources: Bone Marrow, Umbilical Cord).Focus on refractory LN. Potential to promote renal repair (unlike immunosuppressants).Plasma Cell DepletionDaratumumabCD38 (Cytolytic mAb)Phase II / Rescue Therapy.Approved for Multiple Myeloma. Used off-label for severe refractory LN.FelzartamabCD38 (Depleting mAb)Phase II (IGNAZ trial).Showing promise in IgA Nephropathy, now testing in LN.Zetomipzomib (KZR-616)Immunoproteasome InhibitorPhase Ib/II (MISSION Study completed).Selective inhibition reduces toxicity compared to Bortezomib. Targets cytokine production and plasma cells.Ixazomib20S Proteasome (Reversible inhibitor)Phase Ib/II (Completed)Oral proteasome inhibitor. Second-generation agent with a better safety profile than bortezomib; targets plasma cells.Novel Complement InhibitorsRavulizumabC5 (Long-acting mAb)Phase II (SANCTUARY).Approved for PNH/aHUS. Investigating efficacy in TMA associated LN.CrovalimabC5 (Recycling mAb)Phase I/II (Participated in China trials).Subcutaneous administration (Smart antibody).NarsoplimabMASP-2 (Lectin Pathway)Phase II (Investigational).Targets the lectin pathway specifically, sparing classical/alternative pathways.Novel Small Molecules & BiologicsNipocalimab / RozanolixizumabFcRnPhase II (Ongoing in SLE/LN).Accelerates IgG degradation to lower pathogenic autoantibody levels. (Novel "Medical Plasmapheresis" concept).DeucravacitinibTYK2 (Select JAK family)Phase II (PAISLEY - SLE).More selective than Baricitinib; testing if it works for renal involvement.ItolizumabCD6 (T-cell co-stimulation)Phase I/II (EQUALISE).Targets the ALCAM-CD6 pathway; distinct from Abatacept.Litifilimab (BIIB059)BDCA2 (Dendritic Cell)Phase II (LILAC - SLE/CLE).Inhibits Type I IFN production at the source (pDCs). Potential for LN being explored.FenebrutinibBTK (Non-covalent inhibitor)Phase II (Evaluated in SLE/LN)Highly selective reversible inhibitor; aims to suppress B-cell and myeloid cell activation.EvobrutinibBTK (Covalent inhibitor)Phase II (Evaluated in SLE)Covalent irreversible inhibitor demonstrating sustained BTK occupancy; testing efficacy in preventing flares.GuselkumabIL-23p19 (Specific IL-23 antagonist)Phase III (SELUNE Trial ongoing)argets the IL-23/Th17 axis specifically (sparing IL-12/Th1). Key trial for measuring renal outcomes in active LN.UstekinumabIL-12/23 p40 (Dual cytokine antagonist)Phase II CompletedTargets both Th1 and Th17 pathways. Showed promise in Phase II SLE data; paved the way for more specific IL-23 inhibitors in LN.Efavaleukin alfa (AMG 592)IL-2 Mutein (IL-2 receptor agonist)Phase II (Ongoing in SLE)Novel Modality: Designed to selectively expand regulatory T cells to restore immune tolerance without stimulating effector T cells.Co-stimulation BlockadeIscalimab (CFZ533)CD40 (Non-depleting mAb)Phase II CompletedBlocks CD40-CD40L interaction without depleting B cells; demonstrated proteinuria reduction.Dazodalibep (HZN-492)CD40 Ligand (Fusion protein)Phase IISecond-generation CD40L antagonist lacking Fc effector function (reduced thrombotic risk).Rozibafusp alfa (AMG 570)ICOSL / BAFF (Bispecific antibody)Phase IIb (Ongoing in SLE/LN)Dual mechanism: Simultaneously blocks T-cell co-stimulation (ICOSL) and B-cell survival (BAFF). Novel "Two-birds-with-one-stone" approach.LN, Lupus Nephritis; CNI, Calcineurin Inhibitor; FDA, Food and Drug Administration; EMA, European Medicines Agency; PMDA, The Pharmaceuticals and Medical Devices Agency of Japan; NMPA, The National Medical Products Administration of China. MMF, Mycophenolate Mofetil; MPS, Mycophenolate Sodium; IMPDH, Inosine Monophosphate Dehydrogenase; CYC, Cyclophosphamide; HCQ, Hydroxychloroquine; TLR, Toll-Like Receptor; AZA, Azathioprine; RTX, Rituximab; NHL, Non-Hodgkin Lymphoma; RA, Rheumatoid Arthritis; GPA, Granulomatosis with Polyangiitis; CsA, Cyclosporine A; SGLT2, Sodium-Glucose Cotransporter 2; CKD, Chronic Kidney Disease; mTOR, mammalian Target Of Rapamycin; CLL, Chronic Lymphocytic Leukemia; SLE, Systemic Lupus Erythematosus; IFNAR, Type I IFN Receptor; CD40L, CD40 Ligand; PNH, Paroxysmal Nocturnal Hemoglobinuria; CAR-T, Chimeric Antigen Receptor T-cell; CABA, Chimeric Autoantibody Receptor T-cell; NEJM, The New England Journal of Medicine; Nat Med, Nature Medicine; BCMA, B-cell Maturation Antigen; MSCs, Mesenchymal Stem Cells; aHUS, atypical Hemolytic Uremic Syndrome; TMA, thrombotic microangiopathy; FcRn, Neonatal Fc Receptor; BTK, Bruton's Tyrosine Kinase; IL, Interleukin; Th, T helper cell. Overview of therapeutic agents for LN. LN, Lupus Nephritis; CNI, Calcineurin Inhibitor; FDA, Food and Drug Administration; EMA, European Medicines Agency; PMDA, The Pharmaceuticals and Medical Devices Agency of Japan; NMPA, The National Medical Products Administration of China. MMF, Mycophenolate Mofetil; MPS, Mycophenolate Sodium; IMPDH, Inosine Monophosphate Dehydrogenase; CYC, Cyclophosphamide; HCQ, Hydroxychloroquine; TLR, Toll-Like Receptor; AZA, Azathioprine; RTX, Rituximab; NHL, Non-Hodgkin Lymphoma; RA, Rheumatoid Arthritis; GPA, Granulomatosis with Polyangiitis; CsA, Cyclosporine A; SGLT2, Sodium-Glucose Cotransporter 2; CKD, Chronic Kidney Disease; mTOR, mammalian Target Of Rapamycin; CLL, Chronic Lymphocytic Leukemia; SLE, Systemic Lupus Erythematosus; IFNAR, Type I IFN Receptor; CD40L, CD40 Ligand; PNH, Paroxysmal Nocturnal Hemoglobinuria; CAR-T, Chimeric Antigen Receptor T-cell; CABA, Chimeric Autoantibody Receptor T-cell; NEJM, The New England Journal of Medicine; Nat Med, Nature Medicine; BCMA, B-cell Maturation Antigen; MSCs, Mesenchymal Stem Cells; aHUS, atypical Hemolytic Uremic Syndrome; TMA, thrombotic microangiopathy; FcRn, Neonatal Fc Receptor; BTK, Bruton's Tyrosine Kinase; IL, Interleukin; Th, T helper cell. The landscape of clinical trials Temporal and geographic trends The early 2000s were characterized by pivotal trials aiming to optimize cytotoxic regimens, establishing MMF and low-dose CTX as standard induction therapies (7, 8). Subsequently, the late 2000s and post-2010 era witnessed a paradigm shift towards novel mechanism-based therapies, with a surge in industry-sponsored trials focusing on biologics (e.g., B-cell and T-cell costimulation modulators) and small molecules (9–11). Geographically, while North America and Europe have historically led trial recruitment, there has been a significant shift over the past decade with increasing contributions from the Asia-Pacific region, particularly China. This diversification is crucial, given the well-documented ethnic disparities in LN severity and treatment responses (12). Analysis of target populations: the “missing” classes A critical analysis of the enrolled patient populations reveals a distinct polarization based on histological classification. Consistent with the data in Table 1, many interventional trials have exclusively recruited patients with active proliferative LN (Class III/IV), with or without co-existing membranous features. This focus is driven by the aggressive clinical course of proliferative nephritis, which offers quantifiable endpoints (e.g., reduction in proteinuria and active sediment) suitable for efficacy assessment. In contrast, other histological classes remain significantly underrepresented in the clinical trial landscape. Class I and II (Mesangial LN): Specific interventional trials for these classes are virtually non-existent in our dataset. This gap is likely attributable to their relatively indolent clinical course and subtle pathological features, which typically respond well to background SLE therapy without requiring aggressive renal-specific immunosuppression. However, the lack of data leaves uncertainty regarding the optimal management of low-grade proteinuria in these patients. Class I and II (Mesangial LN): Specific interventional trials for these classes are virtually non-existent in our dataset. This gap is likely attributable to their relatively indolent clinical course and subtle pathological features, which typically respond well to background SLE therapy without requiring aggressive renal-specific immunosuppression. However, the lack of data leaves uncertainty regarding the optimal management of low-grade proteinuria in these patients. Class VI (Advanced Sclerotic LN): Similarly, patients with advanced sclerosis (Class VI) are systematically excluded. The irreversible nature of the renal damage in this group raises ethical challenges for testing novel immunosuppressants, as the therapeutic window for recovering renal function is largely closed. Consequently, management for this subgroup remains focused on renal replacement therapy rather than immunomodulation. Class VI (Advanced Sclerotic LN): Similarly, patients with advanced sclerosis (Class VI) are systematically excluded. The irreversible nature of the renal damage in this group raises ethical challenges for testing novel immunosuppressants, as the therapeutic window for recovering renal function is largely closed. Consequently, management for this subgroup remains focused on renal replacement therapy rather than immunomodulation. Pure Membranous LN (Class V): While often included as a subset in mixed cohorts (Class III/IV + V), trials specifically designing primary endpoints for “pure” Class V LN are rare (only 3 trials identified in our dataset focused solely on Class V). Given its distinct pathophysiology (podocyte injury vs. inflammation) and slower progression, it may require different therapeutic strategies than proliferative disease. Pure Membranous LN (Class V): While often included as a subset in mixed cohorts (Class III/IV + V), trials specifically designing primary endpoints for “pure” Class V LN are rare (only 3 trials identified in our dataset focused solely on Class V). Given its distinct pathophysiology (podocyte injury vs. inflammation) and slower progression, it may require different therapeutic strategies than proliferative disease. Evolution of therapeutic mechanisms To comprehensively evaluate the evolving landscape of drug development, we used data from mdata.pharmacodia.com and pharma.bcpmdata.com to investigate both approved and novel therapeutic agents for LN (Table 2). The survey results reveal a clear paradigm shift from broad-spectrum immunosuppression to precision medicine. As illustrated in Figure 1C, the therapeutic targets have diversified significantly. While traditional protocols relied heavily on non-specific inhibition, the current pipeline focuses on specific immunological pathways, predominantly including B cells (35.3%), cytokines (19.1%), and intracellular signaling pathways (8.8%). Notably, recent years have witnessed the rise of novel mechanisms such as complement inhibition (13.2%) and immunoproteasome modulation (16.2%), reflecting a deeper understanding of LN pathogenesis beyond simple autoimmunity. Furthermore, the mode of action is evolving; as shown in Figure 1D, most agents exert reversible inhibitory effects (89.71%), allowing for flexible management of immune suppression, whereas irreversible inhibitors (e.g., certain Bruton’s tyrosine kinase inhibitors) represent a smaller but potent niche. This evolution highlights a strategic pivot towards balancing high efficacy with reduced systemic toxicity. Emerging therapeutic targets and clinical evidence Based on the mechanistic evolution outlined above, we critically assess the clinical potential of key emerging targets, focusing on those that address the limitations of conventional broad-spectrum immunosuppression. B-cell directed therapies CD20 depletion Historically, the use of rituximab (a chimeric Type I anti-CD20 antibody) in LN was met with disappointment in the pivotal Phase III LUNAR trial, which failed to meet its primary endpoint of superior renal response compared to placebo (13, 14). Critics have attributed this failure not to a lack of biological efficacy, as serological improvements were observed, but to limitations in trial design, particularly the confounding effect of high-dose background corticosteroids and incomplete B-cell depletion in tissue niches (15, 16). Addressing these shortcomings, obinutuzumab, a novel humanized Type II anti-CD20 antibody, has recently demonstrated superior efficacy (17). Unlike rituximab, obinutuzumab is glycoengineered to enhance antibody-dependent cellular cytotoxicity (ADCC) and induce direct cell death, resulting in more profound B-cell depletion (18). The Phase III REGENCY trial recently reported positive top-line results, meeting its primary endpoint of Complete Renal Response (CRR) at Week 76 (19). This success validates the hypothesis that deeper and more sustained B-cell depletion is required to translate biological activity into clinical renal remission in LN. B-cell survival factors (BAFF/APRIL) While CD20 antibodies target circulating B cells, they spare long-lived plasma cells. Targeting B-cell survival factors offers a complementary approach. The success of the BLISS-LN trial established belimumab as the first FDA-approved biologic for LN (20, 21). In the pivotal Phase III BLISS-LN trial, belimumab significantly improved the Primary Efficacy Renal Response (PERR) rate compared to placebo and reduced the risk of renal-related events or death, with a safety profile comparable to standard therapy alone. Inhibiting B-lymphocyte stimulator (BLyS), it effectively reduces the transition of naive B cells to autoreactive plasma cells (22). Its inclusion in the 2024 KDIGO guidelines as an add-on therapy underscores its role in enhancing renal response rates and sparing glucocorticoids (23). Taking this mechanism a step further, telitacicept (RC18) targets both BLyS and a proliferation-inducing ligand (APRIL) (24). Since APRIL is crucial for the survival of long-lived plasma cells, which produce autoantibodies, telitacicept theoretically offers broader suppression of the pathogenic humoral response than BLyS inhibition alone. Clinical data from Phase IIb and recent Phase III studies in China have shown promising renal recovery rates and significant reductions in proteinuria, positioning it as a potent alternative for refractory cases (25, 26). The evolution of B-cell therapies highlights a fundamental shift in philosophy. Early trials simply aimed to “remove” B cells, often failing because pathogenic clones persisted in protected tissue niches. The current trend is moving toward “immune reset”. Strategies like obinutuzumab aim for absolute depletion, while emerging CAR-T therapies (discussed in Section 3.4.2) seek to completely purge the immunological memory. However, the next leap forward must address B-cell repopulation: rather than continuous suppression, future trials should investigate how to guide the immune system to repopulate with a “tolerant” B-cell repertoire, potentially through the integration of pharmacogenomic markers such as FCGR3A variants to predict individual response. Complement inhibition Complement activation, evidenced by hypocomplementemia and glomerular deposition of C3/C4, is a hallmark of active LN (27). However, targeting the complement system remains a “double-edged sword”, as excessive inhibition may hinder the clearance of immune complexes and increase infection risks. Terminal pathway blockade (C5 inhibitors) Agents like ravulizumab and crovalimab prevent the formation of the membrane attack complex (MAC) (C5b-9) (28–33). While effective in managing LN-associated thrombotic microangiopathy (TMA), blocking the terminal pathway alone may be “too downstream” to fully suppress C3b-mediated opsonization and inflammatory cell recruitment. Critically, the loss of MAC function introduces a persistent risk of encapsulated bacterial infections (e.g., Neisseria meningitidis), necessitating strict vaccination protocols (34). It’s a significant clinical burden for patients already on complex immunosuppressive regimens. Alternative pathway blockade (factor B inhibitors) The oral Factor B inhibitor iptacopan (NCT05268289) offers a more proximal intervention by blocking Factor B and halting the amplification loop of the alternative pathway (35). This approach theoretically provides superior control over glomerular inflammation compared to terminal blockade alone (36, 37). However, the critical concern remains that proximal inhibition more broadly impairs the body’s natural “clearing” mechanism and anti-bacterial defense, potentially magnifying the infection risks seen with terminal blockade (38). Early classical pathway components (C1q, C4) are protective by facilitating the clearance of apoptotic debris (39). Current trials often struggle to selectively block the “inflammatory” pathways that damage the kidney, while sparing the “protective” pathways that help the body clear metabolic waste. Future success may hinge on temporally specific modulation rather than continuous broad inhibition. Intracellular signaling While biologic agents target cell surface receptors or circulating cytokines, small molecule inhibitors capable of penetrating the cell membrane offer a unique advantage: the ability to block downstream signaling cascades shared by multiple pathogenic receptors. BTK inhibition: dual targeting of B cells and myeloid cells Bruton’s tyrosine kinase (BTK) is a critical node in B-cell receptor (BCR) signaling. However, unlike CD20 antibodies that primarily deplete B cells, BTK inhibitors (BTKi) offer a dual mechanism of action (40). They block BCR signaling in B cells and, crucially, inhibit Fc gamma receptor (FcγR) signaling in myeloid cells (macrophages and monocytes), which are key effectors of renal tissue injury (41, 42). Our dataset highlights zanubrutinib, a highly selective second-generation BTK inhibitor, which is currently under evaluation in a Phase II trial for active proliferative LN (CTR20202662). Owing to its optimized molecular structure, zanubrutinib demonstrates greater selectivity for BTK and a reduced off-target toxicity profile compared to first-generation agents such as ibrutinib (43, 44). The theoretical advantage of BTKi lies in its potential to suppress autoantibody production while simultaneously dampening the intrarenal inflammatory milieu driven by macrophages (45, 46). However, the efficacy signal in SLE/LN has been mixed in the broader class (e.g., failures of other BTKi in SLE phase II trials), suggesting that patient selection based on molecular signatures (e.g., high BTK/myeloid gene expression) may be necessary to unlock their full potential (47–49). JAK inhibition: broad cytokine blockade The pathogenesis of LN involves a complex storm of cytokines (Type I Interferons, IL-6, IL-12/23) (50). Targeting single cytokines often proves insufficient. Janus kinase (JAK) inhibitors can simultaneously interrupt signaling from multiple cytokine receptors, acting as “broad-spectrum” cytokine blockers (51). As shown in Table 1, baricitinib (a JAK1/2 inhibitor) has advanced to Phase III clinical evaluation (e.g., NCT05432531). Early phase data suggested that baricitinib could significantly reduce proteinuria and improve resolution of renal flares (52). The oral bioavailability and rapid onset of action make JAK inhibitors attractive options. However, safety concerns, particularly regarding venous thromboembolism (VTE) and herpes zoster reactivation, require vigilant monitoring (53–55). Balancing the depth of immune suppression with infection risk remains the primary challenge for this class in the context of LN. Novel approaches Beyond established pathways, the LN pipeline is expanding into highly innovative modalities. These therapies represent high-risk, high-reward strategies targeting the fundamental machinery of autoimmunity and tissue repair. Immunoproteasome inhibition The immunoproteasome is highly expressed in immune effector cells and is crucial for cytokine production and plasma cell survival (56). Unlike broad proteasome inhibitors (e.g., bortezomib), which carry significant toxicity, selective immunoproteasome inhibitors aim to target pathogenic cells while sparing constitutive proteasomes in non-immune tissues (57, 58). Our analysis identified zetomipzomib (KZR-616) as a first-in-class selective inhibitor of the immunoproteasome (NCT03393013) (59). Results from the Phase Ib/II MISSION study demonstrated a favorable safety profile and clinically meaningful reductions in proteinuria and SLEDAI scores in patients with active LN, while avoiding the severe peripheral neuropathy and systemic toxicity associated with bortezomib (35). Simultaneously targeting cytokine release and plasma cell function, it offers a dual therapeutic effect distinct from standard immunosuppressants. Chimeric antigen receptor-T cell therapy The concept of “immune reset” in refractory LN is not entirely new, having been fundamentally established by Hematopoietic Stem Cell Transplantation (HSCT). For decades, HSCT has served as the most extensively studied strategy for systemic immune reconstitution in severe SLE/LN, demonstrating the potential for long-term, drug-free remission through the eradication of autoreactive immunological memory (60). However, the widespread clinical application of HSCT has been significantly hampered by its high treatment-related toxicity and the risks associated with non-selective lymphodepletion. Modern engineered cellular therapies, led by CAR-T, represent a precision evolution of this “reset” philosophy. By specifically targeting B-cell lineages (e.g., CD19 or BCMA) rather than the entire immune system, CAR-T aims to achieve the profound efficacy of HSCT while significantly mitigating systemic risks, thus marking a transition from broad-spectrum ablation to targeted immune-reconstitution (61). Recent entries in the registry highlight the initiation of trials using CD19/BCMA bispecific CAR-T cells (e.g., NCT05030779) and fourth-generation CAR-T constructs (e.g., NCT06350110, initiated in 2024) (62). While data are preliminary, early case reports suggest that CAR-T therapy can induce drug-free remission in severe, multidrug-resistant LN. However, the risks of cytokine release syndrome (CRS) and neurotoxicity require careful patient selection and specialized management (63). Mesenchymal stem cell therapy Shifting focus from suppression to repair, MSCs offer immunomodulatory and tissue-regenerative properties (64). Multiple trials in our dataset (e.g., NCT03174587) investigate allogenic MSCs derived from bone marrow or umbilical cord (65). These therapies aim to downregulate autoreactive T/B cells and promote renal tissue repair. While early phases indicate safety, consistent efficacy in large-scale randomized controlled trials (RCTs) remains to be firmly established, with standardization of cell preparation being a key hurdle. Discussion and future perspectives Despite the unprecedented expansion of the therapeutic armamentarium over the past two decades, a definitive “cure” for LN remains elusive. Our review of the global trial landscape reveals a paradox: while the number of targeted agents has surged, the “ceiling” of complete renal response (CRR) in pivotal Phase III trials remains stubbornly around 40-50% at one year (21, 66, 67). This stagnation suggests that simply adding more immunosuppressants to current protocols may yield diminishing returns. Based on the evidence synthesized, we propose three priority areas for future research. Current trials largely treat active LN as a homogeneous entity, recruiting “all-comers” with proliferative histology. However, LN is biologically heterogeneous. For instance, a patient driven by a Type I Interferon signature (responsive to anifrolumab) may differ fundamentally from one driven by B-cell selection survival (responsive to belimumab/telitacicept) (68). Future trials must move beyond histological classification. We advocate for the integration of liquid biopsy (e.g., urine proteomics) and molecular stratification into trial inclusion criteria (69). For example, trials for BTK inhibitors could stratify patients based on myeloid signature expression (42). Only by matching the drug’s mechanism to the patient’s specific immunopathology can we break the 50% response barrier. Most trials analyzed in this review employed an “add-on” design (Standard of Care + Experimental Drug vs. Standard of Care + Placebo). While ethical, this design often masks the efficacy of the novel agent due to the high potency of background high-dose corticosteroids and MMF. The failure of several biologically potent agents (e.g., ocrelizumab, abatacept) in LN may partly be attributed to this “noise”. The success of the recent voclosporin and belimumab trials, which enforced stricter steroid tapering, points the way forward. Future designs should prioritize superiority trials with rapid steroid withdrawal or even head-to-head comparisons against MMF, rather than simply piling new drugs on top of toxic backbones. Proteinuria, the traditional primary endpoint, is a lagging indicator of renal inflammation. Persistent proteinuria can reflect chronic damage rather than active disease, potentially leading to overtreatment. Conversely, histological activity can persist despite clinical remission. There is an urgent need to validate non-invasive biomarkers (e.g., urinary CD163, ALCAM) as surrogate endpoints that can read out renal inflammation in real-time. Furthermore, as “drug-free remission” becomes a tangible goal with therapies like CAR-T, future trials must incorporate long-term follow-up (3–5 years) to assess not just response induction, but the durability of tolerance and the prevention of end-stage kidney disease (ESKD). Beyond clinical and histological stratification, the integration of pharmacogenomics is essential for a truly precise approach to LN management. Genetic variations in drug-metabolizing enzymes and immune receptors significantly influence both therapeutic efficacy and systemic toxicity. For instance, screening for TPMT and NUDT15 polymorphisms is increasingly recognized as a clinical imperative to prevent severe bone marrow suppression in patients receiving azathioprine (70, 71). Similarly, the metabolism of calcineurin inhibitors (CNIs), such as tacrolimus and the recently approved voclosporin, is heavily dictated by CYP3A5 genotypes, where “rapid metabolizers” may fail to reach therapeutic troughs despite standard dosing (72). Furthermore, polymorphisms in the FCGR3A gene, which encodes the FcγRIIIa receptor on effector cells, may modulate the intensity of antibody-dependent cellular cytotoxicity (ADCC), potentially explaining the heterogenous clinical response to B-cell depleting agents like rituximab and obinutuzumab (73, 74). Identifying these single nucleotide polymorphisms (SNPs) before therapy initiation offers a transformative pathway to minimize trial-and-error prescribing and the “ceiling effects” currently observed in LN clinical trials. The last 20 years of clinical trials have transformed LN from a disease managed by blunt immunosuppression to one treated with increasing precision. The approvals of belimumab and voclosporin mark the beginning of this new era. However, the next leap forward will not come from merely discovering new targets, but from revolutionizing how we select patients and design trials. By embracing precision medicine and prioritizing steroid-free remission, the next decade holds the promise of altering the natural history of this devastating disease.